Schneider Institute for Health Policy Heller Graduate School Brandeis University 1 by Donald S. Shepard, Ph.D. Schneider Institute for Health Policy Heller.

Slides:



Advertisements
Similar presentations
Vaccines related epidemiology Programme design and policy options First EpiTrain course in Advanced Epidemiology Jurmala Latvia Hanna Nohynek.
Advertisements

Presented by: $200 $400 $600 $800 $1000 $600 $800 $600 $800MEDI– A, B, C, D PREVENTIVE BENEFITS FUN WITH ACRONYMS POTPOURRI $200 $400 $600 $800 $1000.
Medicare-Medigap-Medicaid Gabriella Hayes  Chantel Ochoa ^_^ Kelle Marshall :D Annysia Hoffman (:
The Medicaid Waiver Program and Participant-Directed Services Making Choice and Control a Reality.
Cost-Effectiveness Using Decision-Analytic Models
The Massachusetts Early Childhood Linkage Initiative (MECLI) John A. Lippitt, Ph.D. Jack P. Shonkoff, M.D. Institute for Child, Youth, and Family Policy.
Welcome, Agenda, Challenges and Potential Solutions Implementing Evidence-Based Practices and Performance Measures for Massachusetts Mental Health Services:
Schneider Institute for Health Policy, The Heller School for Social Policy and Management, Brandeis University Issues in Cost Analysis of Substance Abuse.
1 Presented by Donald S. Shepard, Ph.D. Schneider Institute for Health Policy Heller School, Room 122A, Mail Stop 035 Brandeis University Waltham, MA
Schneider Institute for Health Policy Heller School Brandeis University September by Donald S. Shepard, Ph.D. Schneider Institute for Health Policy.
Schneider Institute for Health Policy Heller School Brandeis University September Donald S. Shepard, Ph.D. Schneider Institute for Health Policy.
The Panel on Cost-Effectiveness in Health and Medicine Marthe Gold City University of London 30 October, 2003.
Schneider Institute for Health Policy Heller Graduate School Brandeis University 1 by Donald S. Shepard, Ph.D. Schneider Institute for Health Policy Heller.
Schneider Institute for Health Policy Heller Graduate School Brandeis University September by Donald S. Shepard, Ph.D. Schneider Institute for Health.
1 by Donald S. Shepard, Ph.D. Schneider Institute for Health Policy Heller School, MS 035 Brandeis University Waltham, MA USA Tel:
1 by Donald S. Shepard, Ph.D. Schneider Institute for Health Policy Heller School, MS 035 Brandeis University Waltham, MA USA Tel:
1 Presented by Donald S. Shepard, Ph.D. Schneider Institute for Health Policy Heller School, Room 122A, Mail Stop 035 Brandeis University Waltham, MA
Cancer Clinical Trials: The Basics. 2 What Are Cancer Clinical Trials? Research studies involving people Try to answer scientific questions and find better.
Copyright ©2004 Pearson Education, Inc. All rights reserved. Chapter 11 Health and Disability Insurance.
Health Economics & Policy 3 rd Edition James W. Henderson Chapter 4 Economic Evaluation in Health Care.
SOCIAL SECURITY SOCIAL SECURITY In Belgium and Germany.
Cancer Program Fewer Montanans experience late stage cancer. Fewer Montanans die of cancer. Metrics Biannual percent of Montanans who are up-to-date with.
A PARTNER YOU CAN TRUST. WHO HAS A REASSURING COMBINATION FOR PARENTS AND CHILDREN?
©UFS Horizon Carpentry Your MetLife Benefit Package.
Balsz School District Employee Benefits Programs
Mr. Woodington’s Money Management II.  Options for individuals seeking health insurance not covered by their employer  Tips for purchasing individual.
Cervical screening Tim Wright Sept 07. Introduction What who when What who when Benefits (evidence) Benefits (evidence) Cost Cost Does it fit wilson’s.
Section 24.2 Participating in Your Healthcare Slide 1 of 18 Objectives Describe how to choose and participate fully in your healthcare. Compare different.
Economic Evaluations, Briefly… CHSC 433 Module 6/Chapter 13 UIC School of Public Health L. Michele Issel, PhD, R N.
Cost Effectiveness Analysis To Enhance Mammography Use Dave Alvey Paul Moley.
HPV & Cervical Cancer Frequently Asked Questions HPV & Cervical Cancer Prevention 2009 International Toolkit.
CHCWG DRAFT March 2, 2006 Hearing from the American People: Preliminary Overview of Sources and Reports March 2006 Caution: Preliminary Data Do not cite.
Cost-Effectiveness Problem l You have a $1.5 billion budget to spend on any combination of these programs:
Clinical Trials. What is a clinical trial? Clinical trials are research studies involving people Used to find better ways to prevent, detect, and treat.
1 Universal Immunization Against Rare Diseases  How much is a child’s life worth?  The individual vs society.
EPIB-591 Screening Jean-François Boivin 29 September
Health Care Reform and its Impact on Michigan Janet Olszewski, Director Michigan Department of Community Health Senate Health Policy Committee May 5, 2010.
Dr. Afnan Younis & A. Al Mazam Dr Afzal Mahmood, Dr Salwa A Tayel KSU, Department of Family & Community Medicine (1434, 2013) TUTORIAL Community Medicine.
Health Care Reform Affordable Care Act Robert Morris MS, MPH Vice President Health Initiatives American Cancer Society.
Copyright ©2004 Pearson Education, Inc. All rights reserved. Chapter 11 Health and Disability Insurance.
Cost-Effectiveness Thresholds Professor of Health Economics
Agribusiness Library LESSON: HEALTH INSURANCE. Objectives 1. Determine the function of health insurance, and define common health insurance terms. 2.
© Family Economics & Financial Education – Updated May 2012 – Types of Insurance – Slide 1 Funded by a grant from Take Charge America, Inc. to the Norton.
Employer Coverage for Immunizations Helen Darling, President Elizabeth Greenbaum, Program Analyst February 7 th, 2006 C enter for Prevention and Health.
Access to Health Care: The Cancer Perspective Daniel E. Smith President, American Cancer Society Cancer Action Network (ACS CAN) November 2007.
1 Presented by Donald S. Shepard, Ph.D. Schneider Institute for Health Policy Heller School, Room 122A, Mail Stop 035 Brandeis University Waltham, MA
Cost-Effectiveness and Cost-Benefit Analysis N287E Spring 2006 Joanne Spetz 31 May 2006.
Region I IPP Infrastructure Updates Advisory Board Meeting June 15, 2010 Boston, MA.
Slide -1 Medicare Prescription Drug Coverage Atlanta Regional Office Centers for Medicare & Medicaid Services September 12, 2005.
Tested Messages to Reach the Unscreened 80% by 2018 Forum Mary Doroshenk, MA, NCCRT Director 1.
Oral Cancer Prevention
Insuring America’s Health: Principles and Recommendations An Institute of Medicine Report Presented By Shoshanna Sofaer, Dr.P.H. School of Public Affairs,
The Role of Perspective in Economic Evaluation for Cancer Prevention Steven Kymes, Ph.D. Research Associate Professor of Ophthalmology And Visual Sciences.
Medicaid and the 4 A’s: Use of 1115 Waivers and State Plan Amendments American Cancer Society Washington, Dc June 5, 2008 Erin Reidy
Hospice Care Kim Lanier. What is hospice care? End-of-life care Provided by health care professionals and volunteers Can take place in the home, at a.
Health Insurance Plans 2.4 Cost is a major concern Health care is over 15% of the gross national product Without insurance the cost of an illness can become.
Highlights of Recent Results from the New Health Insurance Modules of the National Immunization Survey National Vaccine Advisory Committee October 22,
Global Evidence of Comparative Efficiency: Performance of National HIV/AIDS Programs Donald S. Shepard, PhD Wu Zeng, MD, PhD Jon Chilingerian, PhD Carlos.
Health Insurance Plans Intro to Health Science Unit One Lesson 5 Diversified Health Occupations pages.
From EBM to SDM: Michel Labrecque MD PhD Michel Cauchon MD Department of Family and Emergency Medicine Université Laval Teaching how to apply evidence.
Universal Opt-Out Screening for HIV in Health Care Settings, Cost Effectiveness in Action Douglas K. Owens, MD, MS VA Palo Alto Health Care System and.
THE AFFORDABLE CARE ACT: WHAT’S NEXT? Presented by: Michael O’Connor, RHU.
 The Breast and Cervical Cancer Control Program N.C. Cancer Prevention and Control Branch Brittney M. Sala, BS, MPHN Candidate.
The Human Papillomavirus (HPV) Vaccine and State Efforts To Reduce Cervical Cancer Carissa L. Baker; The MayaTech Corporation Jill Freudenwald, M.A.; The.
Cost-Effectiveness of health programs April 10, 2000
Colorectal Cancer Screening Guidelines
More Ontarians need to be screened for colorectal cancer (Sept. 2012)
Cost-Effectiveness of health programs April 17, 2000
Presentation transcript:

Schneider Institute for Health Policy Heller Graduate School Brandeis University 1 by Donald S. Shepard, Ph.D. Schneider Institute for Health Policy Heller School, MS 035 Brandeis University Waltham, MA USA Tel: Fax: Web: Monday, Sept. 24: Applications of cost- effectiveness analysis

Schneider Institute for Health Policy Heller Graduate School Brandeis University 2 Practical information Teaching assistant: Administrative assistant: Linda Purrini, Next to library in Heller Cost of packet: $6.00

Schneider Institute for Health Policy Heller Graduate School Brandeis University 3 Cost-effectiveness ratio Numerator: net use of health resources Denominator: net improvement in QALYs

Schneider Institute for Health Policy Heller Graduate School Brandeis University 4 Standard reference case Standard set of assumptions for consistent analyses Comparator is the status quo Uses a discount rate of 3%

Schneider Institute for Health Policy Heller Graduate School Brandeis University 5 Disease burden exercise Illustrate the calculation of PDLLs from exercise on web site

Schneider Institute for Health Policy Heller Graduate School Brandeis University 6 Vaccinations in Ecuador* Sources of data Incremental cost-effectiveness analysis *Shepard, D. et al, "Cost Effectiveness of Routine and Campaign Vaccinations in Ecuador," Bulletin of the World Health Organization 1989; 67:

Schneider Institute for Health Policy Heller Graduate School Brandeis University 7 Cost per dose by facility and type of strategy

Schneider Institute for Health Policy Heller Graduate School Brandeis University 8 Table 2: Costs and cost-effectiveness of vaccination strategies

Schneider Institute for Health Policy Heller Graduate School Brandeis University 9 Fig. 4: Fully vaccinated coverage rates

Schneider Institute for Health Policy Heller Graduate School Brandeis University 10 Fig. 5: Cost-effectiveness of routine and PREMI strategies

Schneider Institute for Health Policy Heller Graduate School Brandeis University 11 Cost per dose, notes

Schneider Institute for Health Policy Heller Graduate School Brandeis University 12 Cancer Exercise 1 Prepared at the Heller School, Updated September, 2001 Please read the following exercise on colon cancer testing and discuss the questions at the bottom of this page. Suppose that the Massachusetts government has set up a program to test for colon cancer in people enrolled in the state Medicaid program, which offers health care to low income people and their families. The test allows doctors to find colon cancer at an early age. So far, the state government has offered the test to people at high-risk for colon cancer and has prevented many of them from dying of colon cancer. Now, the government wants to offer the test to the rest of the people receiving Medicaid, all of whom are at equally low risk for colon cancer.

Schneider Institute for Health Policy Heller Graduate School Brandeis University 13 Cancer Exercise 2* An advisory committee of doctors was formed to help the government to decide which of two tests to offer the low-risk people. Test 1 is inexpensive but does not always detect cancer in the early stages. Test 2 is more expensive but is better at detecting early cancers. The decision is complicated by budget limitations: the government has only a certain amount of money available to pay for the screening tests. After evaluating the costs and benefits of each test, the doctors have reached the following conclusions. * Adapted from Uble, P.A., DeKay, M.L., Baron, J., Asch, D.A. “Cost-Effectiveness Analysis in a setting of Budget Constraints” The New England Journal of Medicine 1996; 334;

Schneider Institute for Health Policy Heller Graduate School Brandeis University 14 Cancer Exercise 3 Test 1: The budget is just large enough to offer Test 1 to all the low-risk people. With this approach, everyone can receive the test, and 1,000 deaths from colon cancer will be prevented. Test 2: The budget is just large enough to offer Test 2 to half of the low-risk people. With this approach, half the people can receive the test and half cannot, and 1,100 deaths from colon cancer will be prevented. The persons eligible for the screening test would be selected randomly according to their security numbers. Please select which of the tests the advisory committee should recommend and provide the reasons for your selection.